AGL Share PerformanceMore
|52 week high||76.85 05/10/16|
|52 week low||44.00 30/03/17|
|52 week change||-14.00 (-21.88%)|
|4 week volume||1,978,221 27/04/17|
Media for (AGL)
Latest News« previous» nextMore
03/05/2017 - 07:00 RNS
RNS Number: 9768D Angle PLC 03 May 2017 For immediate release 3 May 2017 ANGLE plc ("the Company") BUSINESS UPDATE HIGHLIGHTS PROGRESS WITH PARSORTIX LIQUID BIOPSY Ovarian cancer clinical studies progressing well with patient enrolment completed. Headline data on target for reporting this quarter MD Anderson Cancer Center signed...
04/04/2017 - 07:00 RNS
RNS Number: 4527B Angle PLC 04 April 2017 For immediate release 4 April 2017 ANGLE plc ("the Company") Holding(s) in Company The Company has been informed by Lombard Odier Investment Managers group ("Lombard") that, following its recent acquisition of Henderson Volantis from Henderson Global plc ("Henderson"), Lombard has acquired ordina...
03/04/2017 - 07:00 RNS
RNS Number: 2731B Angle PLC 03 April 2017 For immediate release 3 April 2017 ANGLE plc ("the Company") PARSORTIX ENABLES GENE EXPRESSION ANALYSIS IN HEAD AND NECK CANCER Customer presents clinically relevant results at AACR 2017 with Parsortix where alternative approaches have failed University of Athens, Attikon University H...
30/03/2017 - 07:00 RNS
RNS Number: 9546A Angle PLC 30 March 2017 For immediate release 30 March 2017 ANGLE plc ("the Company") POTENTIAL FOR PREDICTION OF METASTASIS IN PROSTATE CANCER Barts Cancer Institute present new findings at World CDx Europe 2017 conference in London ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is...
13/02/2017 - 08:00 RNS
RNS Number: 6697W Angle PLC 13 February 2017 For immediate release 13 February 2017 ANGLE plc ("the Company") PARSORTIX SELECTED FOR EUROPEAN CANCER-ID PROGRAMME ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that it has been formally selected for CANCER-ID, the European con...
26/01/2017 - 08:01 RNS
RNS Number: 1486V Angle PLC 26 January 2017 For immediate release 26 January 2017 ANGLE plc ("the Company") POSITIVE INTERIM EVALUATION OF OVARIAN CANCER CLINICAL STUDIES Patient enrolment European study now over 90% complete and US study 70% complete Headline data from the full studies expected in Q2, 2017 ANGLE plc (A...
26/01/2017 - 08:00 RNS
RNS Number: 1504V Angle PLC 26 January 2017 For Immediate Release 26 January 2017 ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 31 October 2016 OVARIAN CANCER CLINICAL STUDIES PROGRESSING WELL ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, today announces its unau...
06/01/2017 - 16:39 StockMarketWire
Andrew Newland the Chief Executive of ANGLE Plc (AGL) [LSE:AGL] the specialist medtech company, is to present at th...
|Dividend yield||0 %|
Equity Research (AGL)
InnovaDerma* (IDP.L) 133.5p £15.81m The UK developer of life sciences, beauty and personal care products today provided an update on trading and announces it has secured new e-tailer distribution...
Europa Oil & Gas Hldgs(EOG.L) 5.87p £14.39m The UK and Ireland focussed exploration, development and production company, has signed a Farm-Out Agreement with a wholly owned subsidiary of leading...
Angle’s H117 business update revealed that R&D activities are progressing well, while the company booked further research use sales. The first prospective clinical studies with Angle’s liquid...
- 1 of 7
Latest discussion posts More
“Agree nice - I think that it is known that Parsortix can indicate whether the drugs are working or the dose may be altered to suit the patient. However, the BBC (I haven't ...”▼
“ have helped? Get the impression it wasn't with whats been said on the radio - may be wrong on this. http://www.bbc.co.uk/news/health-39711137 With budgets under ...”▼
Codes & Symbols
|Symbols||AGL, LSE:AGL, AGL.L, AGL:LN, LON:AGL, XLON:AGL|